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Background: Hereditary Hyperferritinaemia Cataract Syndrome (HHCS) is a rare autosomal dominant disease
characterized by increased serum ferritin levels and early onset of bilateral cataract. The disease is caused by
mutations in the Iron-Responsive Element (IRE) located in the 50 untranslated region of L-Ferritin (FTL) mRNA, which
post-transcriptionally regulates ferritin expression.
Methods: We describe two families presenting high serum ferritin levels and juvenile cataract with novel mutations
in the L-ferritin IRE. The mutations were further characterized by in vitro functional studies.
Results: We have identified two novel mutations in the IRE of L-Ferritin causing HHCS: the Badalona +36C > U and
the Heidelberg +52 G > C mutation. Both mutations conferred reduced binding affinity on recombinant Iron
Regulatory Proteins (IPRs) in EMSA experiments. Interestingly, the Badalona +36C > U mutation was found not only
in heterozygosity, as expected for an autosomal dominant disease, but also in the homozygous state in some
affected subjects. Additionally we report an update of all mutations identified so far to cause HHCS.
Conclusions: The Badalona +36C > U and Heidelberg +52 G > C mutations within the L-ferritin IRE only mildly alter
the binding capacity of the Iron Regulatory Proteins but are still causative for the disease.
Keywords: Serum ferritin, Iron metabolism, IRP/IRE regulatory system, Bilateral cataractsBackground
Ferritin is the protein responsible for the storage and
intracellular distribution of iron [1]. It is composed of 24
subunits of two types named H- and L-Ferritin, encoded by
two different genes. The H subunit generates ferroxidase
activity to incorporate iron into the protein shell and the L
subunit facilitates iron-core formation. The synthesis of
these two proteins is controlled post-transcriptionally by
the Iron Regulatory Proteins (IRPs) that bind to the Iron
Responsive Element (IRE), a conserved hairpin-like motif,
located in the 50 untranslated region (UTR) of ferritin
mRNAs [2]. The binding of the IRPs to IREs occurs under
iron-deficient conditions and results in translational repres-
sion of both ferritins. Mutations in the IRE of Ferritin L* Correspondence: msanchez@imppc.org
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reproduction in any medium, provided the or(FTL) mRNA cause reduced IRP binding with concomi-
tant up-regulation of FTL synthesis in the Hereditary
Hyperferritinaemia Cataract Syndrome (HHCS). HHCS
(ORPHA163, OMIM # 600886) was first described in
1995 as an autosomal dominant disease characterized by a
combination of high serum ferritin levels with congenital
bilateral nuclear cataract and the absence of iron overload
[3-6]. Differential diagnosis with hereditary hemochromatosis,
a genetic iron-overload disease, is achieved by genetic ana-
lysis and biochemical measures of serum iron and trans-
ferrin saturation indices, which are not increased in
HHCS. In this work we describe two families of Spanish
and German origin with HHCS caused by novel mutations
in the FTL IRE. Unexpectedly for an autosomal dominant
disease, one of the mutations was detected in the homozy-
gous state in some affected members of the Spanish fam-
ily. In vitro studies indicate a minor disturbance of the
IRP-IRE binding by these mutations.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Proband (III:2, Figure 1A and Table 1) is a 54 year old
woman of Spanish origin presenting a 10-year history of
hyperferritinaemia with no sign of iron overload. Serum
iron, transferrin saturation and liver functional tests
were normal. The patient presents no evidence of hepa-
titis, cirrhosis, diabetes, inflammatory diseases, metabolic
syndrome or neoplasia and genetic testing for HFE heredi-
tary hemochromatosis was negative. She has suffered from
bilateral cataracts since she was 18 years old and underwent
surgery at the age of 39. The proband has one sister (III:4)
and a cousin (III:9) presenting similar clinical features with
hyperferritinaemia and juvenile bilateral cataract (Table 1).
No evidence of elevated serum ferritin was found in four
other sisters of the proband. A deceased maternal uncle
(II:4) had suffered from hyperferritinaemia and cataract
reported as an adult. Notice that the proband’s parents (II:1
and II:2) were first cousins; the mother died from acute
myeloid leukemia and the father from senile dementia and
he had suffered from cataracts which required surgical cor-
rection in adult age. The proband’s mother was never
diagnosed with cataracts but she suffered from severeFigure 1 (A, B) Pedigree trees of the two families with HHCS studied.
unknown sex. Filled symbols indicate affected members and barred symbo
at the molecular level. (C, D) Chromatograms of partial FTL IRE sequences w
that is altered by the pathological mutation. WT denotes wild type sequen
and conventional HGVS nomenclatures are shown.myopia. The proband’s daughter (IV:1), aged 27, shows no
cataracts, but she has moderately elevated serum ferritin
levels above 200 ng/ml and low transferrin saturation
(to be considered with a concomitant hypermenorrhea)
(Table 1). The two sons (IV:2 and IV:3) of the other affected
sister also have moderately elevated serum ferritin levels and
subject IV:2 also shows early signs of cataracts (Table 1).
Pedigree 2
The proband (IV:1, Figure 1B and Table 1) is a 19 year
old man originating from Germany, who was referred to
the medical doctor due to fatigue and difficulties in con-
centrating. He showed high serum ferritin levels with nor-
mal serum iron and transferrin saturation. He presented
with cataracts since the age of 16 and has not undergone
surgery. He does not present any other clinical signs. No
evidence for acute or chronic inflammation was detected
and his liver functional tests and abdominal morphology
at echography medical inspection were normal. The test
for Hereditary Hemochromatosis type 1 (HFE) was nega-
tive and Hereditary Hemochromatosis type 4 (ferroportin
disease) was excluded, with no evidence of pathological
mutations in the SLC40A1 gene. The father (III:2) presents
with similar biochemical findings showing elevated serumSquares indicate males, circles females and rhombus subjects of
ls indicate deceased subjects. Asterisks indicate subjects characterized
here mutations are located. Arrows indicate the nucleotide position
ce according to reference sequence [NCBI:NM_000146.3]. Traditional
Table 1 Biochemical and clinical parameters of the affected members of the two pedigrees studied
Pedigree 1 Pedigree 2
Characteristic III:2 (proband) III:4 III:9 IV:1 IV:2 IV:3 IV:1 (proband) III:2 Normal values
Age at diagnosis (years) 54 53 48 27 27 25 19 40
Sex F F M F M M M M
Hb (g/dl) 13.2 13.1 15.3 13.4 14.3 14.7 15.6 15 ♂ 13,8–18
♀ 12,1–15,1
MCV (fl) 92.3 96 94.1 91.3 85.1 83.4 80.9 80,6 79–99
CRP (mg/L) <5 - 4 <5 <5 - 4 - 5–10
Serum iron (μg/dl) 74 56 79 37 124 243 127 111 37–170
TIBC (μg/dl) 361 - 342 372 327 424 - - 250–450
Serum ferritin (ng/ml) 719 534 952 239 303 447 1290 1260 ♂ 12–300
♀ 12–200
Transferrin (mg/dl) 252 - - 260 229 296 291 300 200–360
Transferrin saturation (%) 20 - 23.1 10 38 57 31 25 20–55
ALT (mU/ml) 28 17 35 21 38 14 - - 14–36
AST (mU/ml) 35 20 40 20 30 30 27 33 9–52
Cataract diagnosis (years) 20 17 20 - 27 - 16 16
Cataract surgery (years) 39 - - - - - - -















Mutation IRE L-ferritin c.[−164C > T] + c.
[−164C > T]
c.[−164C > T] + c.
[−164C > T]
c.[−164C > T] + [=] c.[−164C > T] + [=] c.[−164C > T] + [=] c.[−164C > T] + [=] c.[−148 G > C] + [=] c.[−148 G > C] + [=]
Badalona +36C > U Badalona +36C > U Badalona +36C > U Badalona +36C > U Badalona +36C > U Badalona +36C > T Heidelberg
+52 G > C
Heidelberg
+52 G > C
Reference values are indicated in the last column. The following abbreviations were used: Hb, hemoglobin; MCV, mean corpuscular volume; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, apartate
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at the age of 16 (Table 1). The paternal grandmother (II:2)
and a great-aunt (II:4) had also suffered from cataracts
(Figure 1B).
Written informed consent for genetic analyses was
obtained from the probands and relatives of the two fam-
ilies according to the guidelines of the institution and the
study protocol conforms to the ethical guidelines of the
2002 Helsinki Declaration.
PCR amplification and DNA sequencing
Genetic studies were performed with minor differences for
the two pedigrees.
Genomic DNA was extracted from peripheral blood using
the FlexiGene DNA kit or QIAamp DNA Blood Mini kit
(Qiagen) according to manufacturer’s instructions. PCR
amplification of exon 1 of L-ferritin was performed with
50 ng of genomic DNA using primers reported in
Additional file 1: Table S1. For pedigree 1 the cycling
conditions were: denaturation at 94°C, annealing ranging
from 66 to 60°C, and extension at 72°C, each step for 30 -
seconds and for 30 cycles while for pedigree 2 were: de-
naturation at 95°C, annealing at 58°C, and extension at
72°C, step 1 and 2 for 30 seconds, step 3 for 45 seconds
and for 38 cycles. The resulting amplification product was
verified on a 2% agarose gel. The PCR product was
processed to remove excess dNTPs and unincorporated
primers: for pedigree 1, 8 μl of PCR product were treated
with 10U Exonuclease I and 10U Antarctic Phosphatase
(New England Biolabs) at 37°C for 30 min and the reac-
tion was inactivated by heating at 80°C for 15 min. For
Pedigree 2, 40 μl of PCR product were cleaned up using
the NucleoSpin Gel and PCR Clean-up Kit (Machery-
Nagel) according to manufacturer’s instructions. The puri-
fied PCR product was sequenced using conventional
Sanger method [7] by GATC BIOTECH company (Konstanz,
Germany). Sequencing results were analyzed using Muta-
tion Surveyor software (SoftGenetics LLC) or Chromas
software (Technelysium Pty Ltd).
Plasmid construction
Plasmids for generating EMSA probes were constructed
based on the I-12.CAT plasmid [8] by replacing H-ferritin
IRE with annealed synthetic oligonucleotides corresponding
to the sequences of L-ferritin wild type (WT) or the
mutated versions: +39ΔC, Badalona +36 C >U, Milano +36
C >G, Heidelberg +52 G >C or Torino +29 C >G; oligo-
nucleotide sequence are reported in Additional file 1:
Table S1. DNA templates were linearized with XbaI and
used for in vitro transcription.
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed with a new non-radiolabeled method
([9], and manuscript in preparation) using fluorescently labeledprobes with Aminoallyl-UTP-ATTO-680 (Jena Bioscience).
For direct and competitive EMSAs we include proper
controls such as the +39ΔC deletion construct (positive
control), the Milano +36 C >G mutation [10], a variation at
the same position as the Badalona +36C >U mutation and
the Torino +29C >G mutation [11], the counterpart of the
Heidelberg +52 G >C change. In competitive EMSAs un-
labeled competitors were in vitro transcribed using
MEGAscript T7 kit (Life Technologies) according to the
manufacturer’s instructions. Experimentally for both assays,
100 ng of labeled probe (plus increasing molar excess of
unlabeled competitor probes in the competitive EMSAs),
were heated 3 min at 95°C and then incubated with 120 ng
of recombinant His-tagged IRP1 or IRP2 protein for
15 min at room temperature. Non-specific RNA-protein
interactions were displaced by adding 50 μg of sodium hep-
arin for 10 min. Samples were loaded on a 5% native
acrylamide gel in 1x TBE buffer. RNA-protein complexes
were visualized using Odyssey Infrared Imager (LI-CORE
Bioscience).
RNA folding predictions
RNA folding analysis of IRE motifs was performed using
SIREs Web Server (http://ccbg.imppc.org/sires/, [12]) and
RNAfold Web Server (http://rna.tbi.univie.ac.at/cgi-bin/
RNAfold.cgi, University of Vienna).
Statistical analysis
Values were compared using Student’s t-test for unpaired
data. Differences were defined as statistically significant for
P values less than 0.05.
Results and discussion
Molecular genetic studies
Sequencing of exon 1 of L-ferritin (FTL) in two families
with HHCS revealed the presence of two previously
undescribed sequence variations.
In pedigree 1, a C >U change was detected at position +36
of the upper stem of FTL IRE ([NCBI:NM_000146.3];
c.-164C > T, HGSV nomenclature). Interestingly, the muta-
tion was found to be present in the homozygous state in
two members of this Spanish family (the proband, III:2
and her sister, III:4), while other affected members carry
the change in heterozygosity (Figure 1A and C). To ex-
clude that homozygosity of the mutation may arise from a
“drop of allele mechanism” we have sequenced the FTL
exon 1 using two independent sets of primers and identi-
cal results were obtained (data not shown). Moreover,
possible in trans deletions were assessed with gene dosage
studies by qPCR demonstrating that all studied patients
from pedigree 1 carry two copies of the FTL gene (data
not shown).
Sequencing analysis in pedigree 2 showed a G > C
change at position +52 of the IRE lower stem ([NCBI:
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(Figure 1B and D).
Following the traditional nomenclature for FTL IRE
mutations we refer to these mutations as the “Badalona
+36C >U” and “Heidelberg +52 G >C” mutations, respect-
ively. The presence of either the Badalona or Heidelberg
variation was further validated by PCR-Restriction Fragment
Length Polymorphism, as the +36C >U and +52 G>C
changes introduce a MseI and a HgaI recognition site, re-
spectively (data not shown). Both changes were absent in 50
control subjects, which rules out their being neutral
polymorphisms and supports their causative role for the dis-
ease. Additionally, the sequencing of the complete FTL gene
(coding region and exon-intron boundaries) revealed no
other changes.
The Badalona +36C > U and the Heidelberg +52 G > C
variants show reduced binding of IRP1 and IRP2
The substitution of guanine by cytosine at position +52
(mutation Heidelberg) is predicted to affect base pairing
with the cytosine +29 (Figure 2). However, this is not
obvious for the Badalona +36C > U variation because, in
theory, the presence of cytosine or uracil at position +36
is not expected to alter base pairing with the guanine at
position +47 in the IRE structure (Figure 2), as both C-G
or U-G pairing are possible matching pairs within RNAFigure 2 (A) Schematic representation of the canonical structure of F
apical loop, the cytosine bulge and the upper and lower stems. (B) Pi
HHCS. The two new mutations described here (Badalona +36C > U and He
known deletions causing HHCS.structures. For this mutation we performed folding predic-
tion analysis of the wild-type (WT) and the mutated
sequences, using the SIREs and RNAfold Web Servers
and the result shows that the Badalona +36C >U substitu-
tion increases the folding free energy and opens the struc-
ture of the mutated FTL-IRE, when compared to the
wild-type IRE (Additional file 1: Figure S1).
For both mutations we next examined the ability of the
mutated IRE to bind recombinant IRP1 or IRP2 by electro-
phoretic mobility shift assays (EMSAs). As expected little
IRP binding occurs to the non-functional IRE structure
(+39ΔC, Figure 3A and B, lanes 3), which was used as a
positive control. Importantly, the Badalona +36C >U and
Heidelberg +52 G >C mutations show a reduction of up to
30-40% in the binding to both IRPs (Figure 3A and B, lanes
4 and 6); a similar level of reduction was observed for the
Torino +29C >G mutation ([11], Figure 3A and B, lanes 7),
while the Milano +36C >G mutation [10] reduces its bind-
ing to both IRPs more drastically (Figure 3A and B, lanes
5). Next, we checked the Badalona +36C >U and Heidel-
berg +52 G >C changes by a more stringent assay, a com-
petitive EMSA. The Badalona +36C >U mutation shows a
mild but significant reduction in the efficiency of competi-
tion when compared to wild type unlabeled competitor
(Figure 4A and C, lanes 17–22 compared to 3–8), while its
corresponding control, the Milano +36C >G mutation, isTL IRE depicting important structural parts: the hexanucleotide
cture of the FTL IRE indicating all known causative point mutations in
idelberg +52 G > C) are boxed. (C) Picture of FTL IRE showing the
Figure 3 (A, B) Direct electrophoretic mobility shift assays. Fluorescent labeled probes corresponding to FTL IRE wild type (lanes 1–2), the
mutations +39ΔC (lane 3), Badalona +36C > U (lane 4), Milano +36C > G (lane 5), Heidelberg +52 G > C (lane 6) and Torino +29C > G (lane 7)
were incubated with either rIRP1 (panel A) or rIRP2 (panel B) and the IRP-IRE complex resolved on acrylamide gels. One representative gel is
shown. (C, D) Quantification of the signals in direct EMSAs compared to the wild type FTL IRE signal that was set to 100%. Means ± SD (standard
deviation) of at least three independent experiments are shown. *** p < 0.001.
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tion a small degree of competition is only appreciable at
20x and 40x molar excess of competitor (Figure 4A and C,
lanes 27–28). The Heidelberg +52 G >C mutation also
shows a reduced capacity to compete with the FTL WT
probe and behaves similarly to its corresponding control,
the Torino +29C >G mutation (Figure 4A and C, lanes 31–
36 and 37–42). Results obtained for IRP2 were comparable
and consistent with previous data showing that IRP1 and
IRP2 bind to the L-ferritin IRE with similar affinity (Figures 3
and 4).
Update on HHCS mutations
Hereditary Hyperferritinaemia Cataract Syndrome (ORPH-
A163, OMIM #600866) was first described in 1995 by two
independent groups in Italy and France [3-6]. Additional
file 1: Table S2 summarizes all 37 reported mutations
causing HHCS, including the two novel mutations
reported here. 31 of these are point mutations and 6 are
deletions of different sizes. The majority of the causa-
tive mutations are located in the hexanucleotideloop, followed by the C-bulge region, the upper stem
and the lower stem of the IRE structure (Figure 2).
Other occurrences of inherited unexplained hyper-
ferritinaemia but without cataracts or cataracts diag-
nosed in adult age have been attributed to mutations in
the promoter region, coding region or outside the IRE
motif of FTL [10,13-15].
Several authors have attempted to correlate the clinical
severity of the disease with the position of the IRE muta-
tion [16,17]. An extensive analysis of all described cases
in the literature demonstrates that serum ferritin levels cor-
relate with key IRE substructures (Figure 5). Mutations
affecting the most important IRE structural elements, such
as the hexanucleotide loop or the C-bulge area are detected
in patients with more elevated serum ferritin levels
compared to those patients with mutations affecting the
base pairing of the upper or lower stem of the IRE
(Figure 5). Consistently, our cases with mutations in the
upper (Badalona mutation) and lower (Heidelberg muta-
tion) IRE stem also show intermediate serum ferritin levels
(<1300 ng/ml).
Figure 4 (See legend on next page.)
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Figure 4 (A, C) Competitive EMSAs. Fluorescent labeled FTL wild type probe was incubated with increasing molar excess concentration (1x, 2x,
5x, 10x, 20x and 40x) of unlabeled competitors corresponding to the FTL IRE wild type sequence (lanes 3–8) or the mutants +39ΔC (lanes 9–14),
Badalona +36C > U (lanes 17–22), Milano +36C > G (lanes 23–28), Heidelberg +52 G > C (lanes 31–36) or Torino +29C > G (lanes 37–42). Samples
were then incubated with either rIRP1 (panel A) or rIRP2 (panel C) and resolved on acrylamide gels. One representative gel is shown. F indicates
free probe and N indicates no competitor added. (B, D) Quantification of the signals in competitive EMSAs compared to the signal in lane N
(taken as 100%) are represented in logarithmic scale. Means ± SD of at least three independent experiments are shown.
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reported families and few cases have been described with
de novo mutations [18-24]. Homozygous mutations are
very unusual in HHCS. Indeed, apart from the case we re-
port here, only one other patient has been reported [25].
The geographical distribution of HHCS patients is
worldwide although most cases have been identified in
Europe and the USA; most probably due to the
localization of specialized laboratories [26]. Global
prevalence of the disease has not been clearly defined. In
an attempt to screen more than 3000 blood donors and
almost 13000 patients with cataract [27] no mutations were
detectable in the L-ferritin IRE, suggesting that HHCS is a
rare disease. Its prevalence has been estimated to be 1 in
200000 in the Australian population [19].
Conclusions
In this report we describe two families who have HHCS
due to two novel mutations in the L-ferritin IRE. Unex-
pectedly for an autosomal dominant disease, one of
these families carries the mutation in a homozygousFigure 5 Phenotype-genotype correlation in all described HHCS patie
the IRE mutation in FTL IRE (x-axis). Patients with mutations affecting the a
compared to the ones with mutations in the upper or lower stems. *p < 0.state in some affected subjects. Within this family there
is a tendency for correlation between the genotype of
the subjects and the clinical severity of the disease. How-
ever, this correlation is not perfect due to associated
factors (age, sex, particular clinical history) that make
difficult comparison between subjects. Therefore, we
confirm that, as previously reported, a phenotype/geno-
type correlation in HHCS is difficult to establish due to
concomitant pathologies, clinical penetrance and the fact
that serum ferritin levels are influenced by sex and age
and are subjected to inter and intra-individual variability.
By in vitro assays we show that these mutations mildly
impair IRP-IRE binding; however this minor disturbance
is sufficient for biochemical and clinical symptoms to
occur in the patients. As previously demonstrated by
others we also confirm a tendency for a correlation be-
tween the position of the IRE mutation and the ferritin
levels in this disease.
Moderate hyperferritinaemia is a common feature
found in the adult population and it can be attributed
to different factors including metabolic disease, livernts. Serum ferritin levels (y-axis) are reported against the position of
pical loop or the C-bulge area present higher serum ferritin levels
05; **p < 0.01; ***p < 0.001.
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Some of these cases could be due to the rare genetic dis-
ease HHCS. Therefore, proper tests are important for a
correct diagnosis for hyperferritinemia and to avoid un-
necessary phlebotomy treatment in the case of HHCS.
Additional files
Additional file 1: Table S1. Primer sequences used for genetic
diagnosis and for vector construction in EMSAs. Figure S1. (A, B)
Structure of the IRE motif of the wild type (panel A) or Badalona +36C >
U mutation (panel B). (C, D) RNAfold Web Server folding predictions of
the FTL IRE wild type (panel C) or the Badalona +36C > U change (panel
D). Colored scale indicates the probability of base pairing from 0 (low,
blue) to 1 (high, red). Table S2. Table summarizing all HHCS mutations
described up to now in the literature. The table shows for each mutation,
the conventional nomenclature according to HGVS (corresponding to
[NCBI:NM_000146.3] reference sequence), the traditional nomenclature,
the position in the IRE structure, the number of families and patients
described, the patients’ ancestry and the corresponding published report.
In bold is indicated the first time a mutation was described; § indicates
de novo mutations; NA (not available).
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